Αποτελέσματα Αναζήτησης
The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. …
1 Φεβ 2017 · The NCCN Guidelines for Bone Cancer focus on chordoma, chondrosarcoma, Ewing sarcoma, and osteosarcoma. The guidelines also provide recommendations for treating giant cell tumor of bone (GCTB). Although typically benign, GCTB is locally aggressive and can lead to significant bone destruction.
- Alveolar Rhabdomyosarcoma - Alveolar Soft Part Sarcoma - Angiomatoid fibrous histiocytoma - Angiosarcoma - Atypical Lipomatous Tumor and Well-Differentiated Liposarcoma
29 Αυγ 2014 · NCCN recommendations for systemic recurrences/metastatic chondrosarcoma are as follows : Oligometastatic disease - Surgically excise all sites if possible; consider RT for unresectable sites;...
The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's
Chondrosarcoma is one of the most frequently occurring bone sarcomas of adulthood. The incidence is ∼0.1/100 000 per year, with the most common age being between 30 and 60 years and the male–female ratio is ∼1.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Version 2.2016 Chondrosarcoma CHON-1 aSee Multidisciplinary Team (TEAM-1). bSee Principles of Bone Cancer Management (BONE-A).
